Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study

Table 1

Clinical baseline characteristics of the subjects in this study. (a) Study 1. (b) Study 2.

(a)

Parameter		Parameter
Number	19	HDL-C (mg/dL)
Gender (M/F)	15/4	LDL-C (mg/dL)
Age (years)		γ-GTP (U/L)
Duration (years)		ALT (U/L)
HbA1c (%)		AST (U/L)
PG (mg/dL)		Cre (mg/dL)
BMI (kg/m^2)		BUN (mg/dL)
TG (mg/dL)		eGFR (mL/min/1.73m^2)

(b)

Parameter	Dula continuation	Switching	value
Age (years)			0.200
Gender (M/F)	8/5	10/3	0.394
Duration (years)			0.878
BMI (kg/m^2)			0.798
HbA1c (%)			0.143
PG (mg/dL)			0.555
TG (mg/dL)			0.644
HDL-C (mg/dL)			0.764
LDL-C (mg/dL)			0.521
γ-GTP (U/L)			0.175
ALT (U/L)			0.258
AST (U/L)			0.292
Cre (mg/dL)			0.356
BUN (mg/dL)			0.478
eGFR (mg/dL)			0.166

Abbreviations: BMI: body mass index; PG: plasma glucose; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; γ-GTP: γ-glutamyl transpeptidase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Cre: creatinine; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate. Data are shown as .